Retrospective analysis of the clinical course of patients treated for polymyalgia

被引:11
|
作者
Do-Nguyen, Dung [1 ]
Inderjeeth, Charles A. [1 ,2 ,3 ]
Edelman, Jack [2 ]
Cheah, Patrick [2 ]
机构
[1] Univ Western Australia, North Metropolitan Hlth Serv, Rehabil & Aged Care, Perth, WA, Australia
[2] Univ Western Australia, Sir Charles Gairdner Hosp, Dept Rheumatol, Perth, WA, Australia
[3] Univ Western Australia, Fac Med & Pharmacol, Perth, WA, Australia
关键词
polymyalgia rheumatica; diagnosis; treatment;
D O I
10.2147/OARRR.S38443
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Polymyalgia rheumatica is a chronic inflammatory rheumatic condition, for which the mainstay of treatment is corticosteroids. Here, we review the clinical course of treated patients initially presenting with polymyalgic symptoms. Methods: A retrospective audit was performed of patients who presented with a possible diagnosis of polymyalgia rheumatica. Biochemical markers and prednisone doses were assessed at the initial review, at one month, and 3, 6, and 12 months later. Results: A cohort of 135 patients was identified, comprising 91 females and 44 males of mean age 70.7 years. All patients were treated with oral prednisone at an initial mean dose of 21.3 mg. Mean baseline C-reactive protein level and erythrocyte sedimentation rate were 41.6 mg/ L and 48.6 mm/hour, respectively. Following initiation of therapy, there was a dramatic and sustained decrease in both inflammatory markers. A clinical response was observed in 96.2% of patients, but remission was achieved in only 18.2%. Of those initially diagnosed with polymyalgia rheumatica, 24.8% were subsequently diagnosed with a different rheumatic condition. Conclusion: The excellent response rate to corticosteroid therapy is well established in the literature, but in this research, remission rates were comparatively low during the 12-month study period. The current value of disease-modifying antirheumatic drugs and biologic therapy appears uncertain, and further trials to establish their precise role would be beneficial. A large portion of patients presenting with polymyalgia were eventually diagnosed to have another rheumatic disease, thus reflecting the broad differential diagnosis of polymyalgia symptoms. Polymyalgia symptoms can occur in patients with polymyalgia rheumatica and other rheumatic conditions. This group has a good response to prednisone therapy, although remission at 12 months appears to be uncommon. The gold standard of treatment remains corticosteroid therapy.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 50 条
  • [1] A retrospective analysis of the course and natural history of patients with polymyalgia rheumatica
    Inderjeeth, C.
    Edelman, J.
    Do-Nguyen, D.
    Pitts, E.
    AUSTRALASIAN JOURNAL ON AGEING, 2011, 30 : 12 - 12
  • [2] The clinical course of polymyalgia rheumatica in Chinese
    Li, Wai Ling
    Lo, Yi
    Leung, Moon Ho
    Wong, Woon Sing
    Mok, Mo Yin
    CLINICAL RHEUMATOLOGY, 2010, 29 (02) : 199 - 203
  • [3] The clinical course of polymyalgia rheumatica in Chinese
    Wai Ling Li
    Yi Lo
    Moon Ho Leung
    Woon Sing Wong
    Mo Yin Mok
    Clinical Rheumatology, 2010, 29 : 199 - 203
  • [4] Clinical course and prognostic factors of patients with dedifferentiated liposarcoma: a retrospective analysis
    Casier, Jelena
    Timmermans, Iris
    Laenen, Annouschka
    Hompes, Daphne
    Douchy, Thomas
    Sciot, Raf
    Christiaens, Melissa
    Wafa, Hazem
    Schoeffski, Patrick
    BMC CANCER, 2025, 25 (01)
  • [5] Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin:: A retrospective analysis
    Colle, I
    Durand, F
    Pessione, F
    Rassiat, E
    Bernuau, J
    Barrière, E
    Lebrec, D
    Valla, DC
    Moreau, R
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (08) : 882 - 888
  • [6] Retrospective Analysis of Factors Associated with Fracture in 714 Patients with Polymyalgia Rheumatica
    Ark, Rajiv
    Talash, Khojasta
    Bukhari, Marwan
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2022, 2022
  • [7] Course of illness and outcomes in older COVID-19 patients treated with HFNC: a retrospective analysis
    Deng, Liehua
    Lei, Shaoqing
    Wang, Xiaoyan
    Jiang, Fang
    Lubarsky, David A.
    Zhang, Liangqing
    Liu, Danyong
    Han, Conghua
    Zhou, Dunrong
    Wang, Zheng
    Sun, Xiaocong
    Zhang, Yuanli
    Cheung, Chi Wai
    Wang, Sheng
    Xia, Zhongyuan
    Applegate, Richard L.
    Tang, Jing
    Mai, Zhenhua
    Liu, Hong
    Xia, Zhengyuan
    AGING-US, 2021, 13 (12): : 15801 - 15814
  • [8] Clinical trials to clinical practice: retrospective analysis of 25 patients with bipolar mania treated with aripiprazole
    Rana, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S410 - S411
  • [9] Clinical analysis of gender and pre-existing diabetes mellitus in patients with polymyalgia rheumatica: A retrospective study in a Japanese population
    Horai, Yoshiro
    Otsuka, Mizuna
    Kawahara, Chieko
    Iwanaga, Nozomi
    Yamasaki, Yusuke
    Watanobe, Taro
    Yasui, Junichi
    Saishoji, Yusuke
    Torisu, Yuichi
    Mori, Takahiro
    Mori, Hideki
    Izumi, Yasumori
    Kawakami, Atsushi
    MODERN RHEUMATOLOGY, 2023, 33 (01) : 181 - 186
  • [10] DOES THE LOCALIZATION OF THE EPILEPTOGENIC ZONE DETERMINE CLINICAL COURSE AND CLINICAL FACTORS OF INTRACTABLE EPILEPSIES: A RETROSPECTIVE INVESTIGATION OF SURGICALLY TREATED PATIENTS
    Rohracher, A.
    Unterberger, I
    Ortler, M.
    Bauer, G.
    Kuchukhidze, G.
    Walser, G.
    Dobesberger, J.
    Hoefler, J.
    Granbichler, C.
    Kalss, G.
    Trinka, E.
    EPILEPSIA, 2013, 54 : 79 - 80